Amgen Inc. (NASDAQ:AMGN) Stock Holdings Increased by Bank of Montreal Can

Bank of Montreal Can lifted its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 3.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,344,419 shares of the medical research company's stock after purchasing an additional 46,030 shares during the period. Bank of Montreal Can owned about 0.25% of Amgen worth $350,409,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Norges Bank acquired a new position in Amgen in the fourth quarter valued at approximately $1,541,991,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Amgen by 25.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company's stock worth $3,441,909,000 after purchasing an additional 2,672,975 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Amgen during the 4th quarter valued at approximately $401,913,000. Franklin Resources Inc. grew its stake in Amgen by 52.7% during the 4th quarter. Franklin Resources Inc. now owns 3,291,975 shares of the medical research company's stock worth $858,020,000 after buying an additional 1,135,884 shares during the last quarter. Finally, Van ECK Associates Corp increased its position in Amgen by 263.8% in the fourth quarter. Van ECK Associates Corp now owns 1,038,593 shares of the medical research company's stock worth $270,699,000 after buying an additional 753,147 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the transaction, the senior vice president now directly owns 7,210 shares in the company, valued at approximately $2,195,228.70. The trade was a 18.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP David M. Reese sold 25,225 shares of the stock in a transaction on Friday, February 21st. The shares were sold at an average price of $304.44, for a total value of $7,679,499.00. Following the completion of the sale, the executive vice president now owns 36,922 shares of the company's stock, valued at $11,240,533.68. The trade was a 40.59 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 69,341 shares of company stock valued at $20,644,335. 0.69% of the stock is currently owned by corporate insiders.

Amgen Price Performance

NASDAQ:AMGN traded up $4.57 during trading hours on Friday, reaching $285.98. 3,466,932 shares of the company's stock were exchanged, compared to its average volume of 2,777,164. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The company has a market capitalization of $153.76 billion, a P/E ratio of 37.88, a price-to-earnings-growth ratio of 2.63 and a beta of 0.59. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The business's 50-day simple moving average is $304.33 and its two-hundred day simple moving average is $295.27.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Sell-side analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 annualized dividend and a yield of 3.33%. Amgen's payout ratio is presently 126.09%.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. UBS Group reissued a "hold" rating on shares of Amgen in a report on Wednesday, February 12th. Johnson Rice set a $294.00 target price on shares of Amgen in a research report on Wednesday, March 5th. StockNews.com upgraded shares of Amgen from a "buy" rating to a "strong-buy" rating in a research note on Wednesday. Bank of America increased their price objective on Amgen from $275.00 to $294.00 and gave the stock an "underperform" rating in a report on Wednesday, March 5th. Finally, Truist Financial cut their target price on Amgen from $333.00 to $298.00 and set a "hold" rating on the stock in a research note on Wednesday, January 8th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $315.22.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.